Second phase 3 study results for LMTX® published in the Journal of Alzheimer’s Disease

(IOS Press) TauRx Therapeutics Ltd today reported the full results from its second Phase 3 clinical study of LMTX®, the first tau aggregation inhibitor in Alzheimer's disease, published online in the Journal of Alzheimer's Disease.

Comments

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

%d bloggers like this: